- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
- Lisata Therapeutics to Present at BIO CEO & Investor Conference
- Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
- Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
- Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
More ▼
Key statistics
On Tuesday, Lisata Therapeutics Inc (LSTA:NAQ) closed at 2.65, 35.90% above the 52 week low of 1.95 set on Sep 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.57 |
---|---|
High | 2.81 |
Low | 2.55 |
Bid | 2.65 |
Offer | 3.02 |
Previous close | 2.67 |
Average volume | 8.19k |
---|---|
Shares outstanding | 8.31m |
Free float | 6.73m |
P/E (TTM) | -- |
Market cap | 22.18m USD |
EPS (TTM) | -2.58 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 20:59 BST.
More ▼